Clinical Trials Logo

Filter by:
NCT ID: NCT00036556 Completed - Prostatic Neoplasms Clinical Trials

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Start date: June 2001
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

NCT ID: NCT00036543 Completed - Prostate Cancer Clinical Trials

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Start date: May 2001
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

NCT ID: NCT00036179 Completed - Candidiasis Clinical Trials

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Start date: February 27, 1999
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.

NCT ID: NCT00036166 Completed - Aspergillosis Clinical Trials

Study of FK463 for the Treatment of Invasive Aspergillosis

Start date: January 29, 1999
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.

NCT ID: NCT00035308 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.

NCT ID: NCT00035035 Completed - Clinical trials for Pancreatic Neoplasms

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Start date: n/a
Phase: Phase 3
Study type: Interventional

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

NCT ID: NCT00034268 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2. The safety of LY900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combination of these three drugs. 3. Whether LY900003 plus gemcitabine and cisplatin can make your tumor smaller or disappear, and for how long, compared with gemcitabine and cisplatin alone. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate LY900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed. LY900003 may not add any benefit to gemcitabine plus cisplatin.

NCT ID: NCT00033904 Completed - Clinical trials for Renal Cell Carcinoma

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

Start date: June 2000
Phase: Phase 3
Study type: Interventional

Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.

NCT ID: NCT00031486 Completed - Encephalitis Clinical Trials

Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir

Start date: September 2000
Phase: Phase 3
Study type: Interventional

This study involves patients 12 years and older who have been diagnosed with herpes simplex encephalitis (HSE) by a specific laboratory test and have completed treatment or are being treated with intravenous (given through a needle inserted into a vein) acyclovir. The purpose of the study is to determine if treatment with 4 tablets, 500 milligrams each, of valacyclovir given 3 times daily by mouth for 90 days is both effective and safe after completing intravenous acyclovir treatment and if it can increase survival with or without mild impairment of the brain and mental functions. Participants will be assigned to either drug or placebo (inactive substance) randomly (by chance). Study procedures will include blood samples and lumbar punctures (procedure in which a needle is inserted into the lower back to collect cerebral spinal fluid). Subjects will participate for up to 24 months.

NCT ID: NCT00030719 Recruiting - Neuroblastoma Clinical Trials

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Start date: December 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining isotretinoin and monoclonal antibodies may kill any remaining tumor cells following surgery. It is not yet known which treatment regimen is more effective in treating neuroblastoma. PURPOSE: This randomized phase III trial is studying how well combination chemotherapy with or without filgrastim before surgery, high-dose chemotherapy, and radiation therapy followed by isotretinoin with or without monoclonal antibody work in treating patients with neuroblastoma.